Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine.

@article{Sparreboom2004EffectsOA,
  title={Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine.},
  author={Alex Sparreboom and Huachen Chen and Milin R. Acharya and Adrian M. Senderowicz and Richard A. Messmann and Takashi Kuwabara and David J Venzon and Anthony J. Murgo and Donna J. Headlee and Edward A. Sausville and William D. Figg},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2004},
  volume={10 20},
  pages={6840-6}
}
OBJECTIVE UCN-01 (7-hydroxystaurosporine) is a small molecule cyclin-dependent kinase modulator currently under clinical development as an anticancer agent. In vitro studies have demonstrated that UCN-01 is strongly bound to the acute-phase reactant alpha (1)-acid glycoprotein (AAG). Here, we examined the role of protein binding as a determinant of the pharmacokinetic behavior of UCN-01 in patients. EXPERIMENTAL DESIGN Pharmacokinetic data were obtained from a group of 41 patients with cancer… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2003
View 1 Excerpt

Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2003
View 1 Excerpt

The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy • 2003
View 2 Excerpts

Similar Papers

Loading similar papers…